Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Pro and Con Article

All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the PRO

Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany; NCT Clinical Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg
NCT Clinical Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg
Haematologica Early view Jan 15, 2026 https://doi.org/10.3324/haematol.2025.288785

Abstract

Not available.

Figures & Tables

Article Information

Early view : Pro and Con Article
 
DOI
https://doi.org/10.3324/haematol.2025.288785
 
Published
2026-01-15
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2026 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
50
PDF Downloads
30

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online